Vnitr Lek 2024, 70(6):366-369 | DOI: 10.36290/vnl.2024.073

Cardiovascular risks of systemic corticosteroid therapy

Jiří Vymětal, Pavel Horák
3. interní klinika - nefrologická, revmatologická a endokrinologická FN Olomouc

Glucocorticoids are a group of drugs used to treat a wide range of immune-mediated diseases and conditions in many fields, including acute conditions. On the one hand, they are very effective drugs, but on the other hand, they also have many side effects, especially when used for long periods of time and at higher doses. In this communication, we present a review of the knowledge and evidence on the cardiovascular risks of glucocorticoid treatment and their clinical forms, which are still perceived more in the context of classical risk factors for cardiovascular disease, such as hypertension, dyslipidemia, etc.

Keywords: glucocorticoids, cardiovascular risk.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vymětal J, Horák P. Cardiovascular risks of systemic corticosteroid therapy. Vnitr Lek. 2024;70(6):366-369. doi: 10.36290/vnl.2024.073.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S-5-12.
    2. Ocon AJ, Reed G, Pappas DA et al. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80(12):1522-9. Go to original source... Go to PubMed...
    3. Smith DJF, Prabhudev H, Choudhury S et al. Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement. Endocr Connect. 2017;6(8):766-72. Go to original source... Go to PubMed...
    4. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31(5):1213-24. Go to original source... Go to PubMed...
    5. Huscher D, Thiele K, Gromnica-Ihle E et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24. Go to original source... Go to PubMed...
    6. Mebrahtu TF, Morgan AW, West RM et al. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192(12):E295-E301. Go to original source... Go to PubMed...
    7. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(1):72-5. Go to original source... Go to PubMed...
    8. Palmowski A, Boers M, Kirwan J et al. The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis. Ann Intern Med. 2024;177(4):546-7. Go to original source... Go to PubMed...
    9. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl. 1992;37:S34-7.
    10. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859-65. Go to original source... Go to PubMed...
    11. Ajeganova S, Svensson B, Hafström I et al. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4):e004259. Go to original source... Go to PubMed...
    12. Pujades-Rodriguez M, Morgan AW, Cubbon RM et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med. 2020;17(12):e1003432. Go to original source... Go to PubMed...
    13. Aviña-Zubieta JA, Abrahamowicz M, De Vera MA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52(1):68-75. Go to original source... Go to PubMed...
    14. So H, Lam TO, Meng H et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82(11):1387-93. Go to original source... Go to PubMed...
    15. van der Hooft CS, Heeringa J, Brusselle GG et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20. Go to original source... Go to PubMed...
    16. Christiansen CF, Christensen S, Mehnert F et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169(18):1677-83. Go to original source... Go to PubMed...
    17. Akikusa JD, Feldman BM, Gross GJ et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics. 2007;119(3):e778-82. Go to original source... Go to PubMed...
    18. White KP, Driscoll MS, Rothe MJ et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30(5 Pt 1):768-73. Go to original source... Go to PubMed...
    19. Majoor CJ, Kamphuisen PW, Zwinderman AH et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J. 2013;42(3):655-61. Go to original source... Go to PubMed...
    20. Waljee AK, Rogers MA, Lin P et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. Go to original source... Go to PubMed...
    21. Lieber BA, Han J, Appelboom G et al. Association of Steroid Use with Deep Venous Thrombosis and Pulmonary Embolism in Neurosurgical Patients: A National Database Analysis. World Neurosurg. 2016;89:126-32. Go to original source... Go to PubMed...
    22. Petri M, Perez-Gutthann S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93(5):513-9. Go to original source... Go to PubMed...
    23. Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-79. Go to original source... Go to PubMed...
    24. Kršek M. [Systemic glucocorticoids treatment: practical view]. Vnitr Lek. 2015;61(10):905-13.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.